Midatech forms PharMida AG, a New Life Science Subsidiary Applying Nanotechnology to Drug Discovery and Development
Financing from Swiss investors begins long-term nanoparticle drug development programme
19-Nov-2008 -
Midatech Group announced the formation of a Basel-based Swiss drug development subsidiary, PharMida AG. Formation of this subsidiary follows an investment by a group of Switzerland-based private investors into Midatech Ltd. The mandate of PharMida is to develop a strong portfolio of clinically ...
cardiology
drug development
Formation
+4